Centre gives custom cushion to supply strained Pharma, MedTech manufacturers

New Delhi:  In an effort to curb the incremental cost burden arising from the in West Asia, the Centre has announced customs duty exemptions on 40 petrochemical inputs, providing relief to pharmaceutical and medtech manufacturers who rely on these inputs to produce finished goods

The Union Finance Ministry has released the full list of products eligible for customs duty exemption. The temporary measure, effective until June 30, is intended to ensure the continued availability of critical petrochemical inputs for domestic industries.

Welcoming the move, the domestic pharma giants lobby, Indian Pharmaceutical Alliance (IPA) in a statement said, “The ongoing West Asia conflict is having an impact on the timely movement of products and in this difficult situation, we appreciate the proactive efforts to mitigate potential supply-related disruptions.”

Speaking for medical device makers, Rajiv Nath, Forum Coordinator, AiMeD noted, this targeted relief, directly addresses the severe inflationary cost pressures faced by medical devices manufacturers due to supply chain disruptions and will lower input costs for our sector, amid global volatility.

“Raw materials such as Polypropylene, ABS, Polycarbonate, and PVC resin form the backbone of medical consumables manufacturing, and their exemption provides much-needed relief to domestic manufacturers,” Himanshu Baid, MD, Poly Medicure added.

The ongoing conflict in West Asia has delivered a major blow to drug and device manufacturers in India, with the prices of inputs used to make medicines have surged by up to 50 percent as most raw materials are derived from petrochemical feedstocks.

For drug manufacturers, shortages of polymers and PVC have created difficulties in producing low-risk consumables, while a supply shortage of helium gas has disrupted the manufacturing of MRI scanners.

Last month, AiMeD had approached the Union Ministry of Commerce seeking a refund of customs duties on imports to offset the rising incremental cost burden caused by higher freight charges and shortage of goods due to the near‑effective blockade of the Strait of Hormuz.

To further ease cost pressure on manufacturers, industry representatives have reiterated their long-standing demand to lower GST liability on raw materials— APIs, solvents, and reagents— which are currently charged the highest effective rate: 18 per cent.

According to Nath , reducing GST from the current 18 per cent on inputs to 5 per cent would further mitigate war-induced cost escalations and improve the competitiveness of made in India goods in the international market.

Meanwhile, to ensure uninterrupted supply of critical goods, IPA has called for setting an ‘Empowered Committees of Secretaries’ for continuous monitoring and better coordination among all stakeholders.

Related Posts

Apollo Navi Mumbai launches geriatric oncology clinic

With a dedicated Geriatric Oncology Clinic, Apollo Hospitals Navi Mumbai brings specialised geriatric cancer care to the private healthcare setting in Navi Mumbai. With the launch of the Geriatric Oncology…

Maharashtra FDA cancels licences of 62 pharma units, 141 chemist shops

Mumbai: The Food and Drug Administration (FDA) has cracked down on medical stores violating drug-sale rules, suspending 599 licences and cancelling another 141 after inspecting 2,295 retail establishments across the…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Apollo Navi Mumbai launches geriatric oncology clinic

Apollo Navi Mumbai launches geriatric oncology clinic

Maharashtra FDA cancels licences of 62 pharma units, 141 chemist shops

Maharashtra FDA cancels licences of 62 pharma units, 141 chemist shops

Himachal DCA honoured with ‘Regulatory Excellence Award’ at iPHEX 2026

Himachal DCA honoured with ‘Regulatory Excellence Award’ at iPHEX 2026

Baddi pharma firm loses licence after 1,200-kg tapentadol haul

Baddi pharma firm loses licence after 1,200-kg tapentadol haul

US FDA takes steps to maintain newborn access to life-saving starter nutrition products

US FDA takes steps to maintain newborn access to life-saving starter nutrition products

Mankind Pharma launches campaign to inspire 1 crore Indians to pledge for organ donation